https://www.selleckchem.com/pr....oducts/arry-380-ont-
Propranolol is a non-selective beta-adrenergic receptor antagonist. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2b trial enrolled participants aged 18-65 years with temporomandibular disorder (TMD) myalgia to evaluate efficacy and safety of propranolol compared with placebo in reducing facial pain. Participants were randomized 11 to either extended-release propranolol hydrochloride (60 mg, BID) or placebo. The primary endpoint was change in facial pain index (FPI = facial pain intensity mu
Like
Comment
Share
